nach oben

Annals of Hematology

Erschienen in:

01.02.2005 | Original Article

Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution

verfasst von: S. Müller, P. Schütt, P. Bojko, M. R. Nowrousian, J. Hense, S. Seeber, T. Moritz

Erschienen in: Annals of Hematology | Ausgabe 2/2005

Einloggen, um Zugang zu erhalten

Abstract

Hemolytic uremic syndrome (HUS) has been described following the administration of multiple antineoplastic agents, most notably mitomycin C. More recently, several cases of gemcitabine-induced HUS have been observed with the overall incidence of gemcitabine-induced HUS estimated at 0.015–0.25%. We here report on four patients who developed HUS following gemcitabine therapy at our institution within the last year (incidence 1.4%). All these patients had advanced-stage disease, were heavily pretreated, and received prolonged gemcitabine application, suggesting that in this subgroup of patients HUS may be more frequently encountered than documented so far.

Allford SL, Hunt BJ, Rose P, Machin SJ (2003) Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 120:556–573CrossRefPubMed

Bell WR, Braine HG, Ness PM, Kickler TS (1991) Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 325:398–403PubMed

Borghardt EJ, Kirchertz EJ, Marten I, Fenchel K (1998) Protein A-immunoadsorption in chemotherapy associated hemolytic-uremic syndrome. Transfus Sci 19 [Suppl]:5–7CrossRefPubMed

Brodowicz T, Breiteneder S, Wiltschke C, Zielinski CC (1997) Gemcitabine-induced hemolytic uremic syndrome: a case report. J Natl Cancer Inst 89:1895–1896CrossRefPubMed

Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J (1999) A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 85:2023–2032PubMed

Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R (1955) Hemolytic-uremic syndrome: bilateral kidney cortex necrosis in acute acquired hemolytic anemia, Schweiz Med Wochenschr 85:905–909PubMed

Gordon LI, Kwaan HC (1997) Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 34:140–147PubMed

Guchelaar HJ, Richel DJ, van Knapen A (1996) Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev 22:15–31CrossRefPubMed

Hui YF, Reitz J (1997) Gemcitabine: a cytidine analogue active against solid tumors. Am J Health Syst Pharm 54:162–170 (quiz 197-198)PubMed

10.

Lesesne JB, Rothschild N, Erickson B, Korec S, Sisk R, Keller J, Arbus M, Woolley PV, Chiazze L, Schein PS et al (1989) Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 7:781–789PubMed

11.

Melnyk AM, Solez K, Kjellstrand CM (1995) Adult hemolytic-uremic syndrome. A review of 37 cases. Arch Intern Med 155:2077–2084CrossRefPubMed

12.

Meyrier A, Becquemont L, Weill B, Callard P, Rainfray M (1991) Hemolytic-uremic syndrome with anticardiolipin antibodies revealing paraneoplastic systemic scleroderma. Nephron 59:493–496PubMed

13.

Palmisano J, Agraharkar M, Kaplan AA (1998) Successful treatment of cisplatin-induced hemolytic uremic syndrome with therapeutic plasma exchange. Am J Kidney Dis 32:314–317PubMed

14.

Remuzzi G, Ruggenenti P (1995) The hemolytic uremic syndrome. Kidney Int 48:2–19PubMed

15.

Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325:393–397PubMed

16.

Schiebe ME, Hoffmann W, Belka C, Bamberg M (1998) Mitomycin C-related hemolytic uremic syndrome in cancer patients. Anticancer Drugs 9:433–435PubMed

17.

Schieppati A, Ruggenenti P, Cornejo RP, Ferrario F, Gregorini G, Zucchelli P, Rossi E, Remuzzi G (1992) Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome. J Am Soc Nephrol 2:1640–1644PubMed

18.

Segonds A, Louradour N, Suc JM, Orfila C (1979) Postpartum hemolytic uremic syndrome: a study of three cases with a review of the literature. Clin Nephrol 12:229–242PubMed

19.

Serke S, Riess H, Oettle H, Huhn D (1999) Elevated reticulocyte count—a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report. Br J Cancer 79:1519–1521CrossRefPubMed

20.

Siegler RL (1995) The hemolytic uremic syndrome. Pediatr Clin North Am 42:1505–1529PubMed

21.

Snyder HW, Jr., Mittelman A, Oral A, Messerschmidt GL, Henry DH, Korec S, Bertram JH, Guthrie TH, Jr., Ciavarella D, Wuest D et al (1993) Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer 71:1882–1892PubMed

22.

Verwey J, Boven E, van der Meulen J, Pinedo HM (1984) Recovery from mitomycin C-induced hemolytic uremic syndrome. A case report. Cancer 54:2878–2881PubMed

23.

von Baeyer H (2002) Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher 6:320–328CrossRefPubMed

Titel: Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution
verfasst von: S. Müller
P. Schütt
P. Bojko
M. R. Nowrousian
J. Hense
S. Seeber
T. Moritz
Publikationsdatum: 01.02.2005
Verlag: Springer-Verlag
Erschienen in: Annals of Hematology / Ausgabe 2/2005
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-004-0938-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2005

Pure red cell aplasia with a clonal T-cell disorder

Distribution of the C282Y and H63D polymorphisms in hereditary hemochromatosis patients from the French Basque Country

Clinical relevance of vascular endothelial growth factor levels in sickle cell disease

Cytogenetic response to pipobroman in Philadelphia-positive chronic myeloid leukemia with thrombocythemic onset

Mesenteric venous thrombosis in a patient with congenital afibrinogenemia and diffuse peritonitis

Inflammation markers and liver dysfunction

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin